We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Doximity (DOCS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Read MoreHide Full Article
In the latest trading session, Doximity (DOCS - Free Report) closed at $19.85, marking a -4.7% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.01%. On the other hand, the Dow registered a gain of 0.14%, and the technology-centric Nasdaq decreased by 0.46%.
Shares of the medical social networking site witnessed a gain of 2.81% over the previous month, trailing the performance of the Medical sector with its gain of 2.92%, and outperforming the S&P 500's loss of 1.4%.
Market participants will be closely following the financial results of Doximity in its upcoming release. The company is expected to report EPS of $0.29, down 19.44% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $151.7 million, up 3.97% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.39 per share and a revenue of $670.18 million, indicating changes of -8.55% and +3.93%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Doximity. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Doximity possesses a Zacks Rank of #5 (Strong Sell).
Looking at its valuation, Doximity is holding a Forward P/E ratio of 15. This indicates a discount in contrast to its industry's Forward P/E of 25.92.
It is also worth noting that DOCS currently has a PEG ratio of 2.14. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Medical Info Systems industry was having an average PEG ratio of 1.96.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 167, putting it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Doximity (DOCS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, Doximity (DOCS - Free Report) closed at $19.85, marking a -4.7% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.01%. On the other hand, the Dow registered a gain of 0.14%, and the technology-centric Nasdaq decreased by 0.46%.
Shares of the medical social networking site witnessed a gain of 2.81% over the previous month, trailing the performance of the Medical sector with its gain of 2.92%, and outperforming the S&P 500's loss of 1.4%.
Market participants will be closely following the financial results of Doximity in its upcoming release. The company is expected to report EPS of $0.29, down 19.44% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $151.7 million, up 3.97% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.39 per share and a revenue of $670.18 million, indicating changes of -8.55% and +3.93%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Doximity. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Doximity possesses a Zacks Rank of #5 (Strong Sell).
Looking at its valuation, Doximity is holding a Forward P/E ratio of 15. This indicates a discount in contrast to its industry's Forward P/E of 25.92.
It is also worth noting that DOCS currently has a PEG ratio of 2.14. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Medical Info Systems industry was having an average PEG ratio of 1.96.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 167, putting it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.